|
Arlen M, et al. The identification and development of specific monoclonal antibodies to squamous cell carcinoma. Critical Rev. Immunol. 21:205-214, (2001). Arlen M, and Tsang, K. The nature of the monoclonal antibodies derived from immunogenic membrane antigens of human colon carcinoma origin. J. Tumor Marker Oncol. 5:313-319, (1990). Char D, Hollinshead A, and Herberman R. Skin tests with soluble melanoma antigens in patients with choroidal tumors. Cancer 40:1650-1654 (1977). Hitchcock M, Hollinshead A, Chretien P, and Rizzoli H. Soluble membrane antigens of brain tumors. Controlled testing for cell-mediated immune responses in a long surviving glioblastoma multiforme patient. Cancer 40:660-666, (1977). Hollinshead A, et al. Methods of preparing epitopes of tumor associated antigens. U.S. Patent No. 4,810,781 (1989). Hollinshead A, Takita H, Stewart T, and Raman S. Specific active lung cancer immunotherapy. Immune correlates of clinical responses and an update of immunotherapy trials evaluations. Cancer 62:1662-1671, Hollinshead A, Stewart TH, Takita H, Dalbow M, Concannon J. Adjuvant specific active lung cancer immunotherapy trials. Tumor associated antigens. Cancer 60(6): 1249-62, (1987). Hollinshead A, Elias EG, Arlen M, et al. Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor–associated antigens (TAA). A phase I clinical trial. Cancer 56(3):480-9, (1985). Hollinshead A, Arlen M, Yonemoto R, et al. Pilot studies using melanoma tumor-associated antigens (TAA) in specific active immunochemotherapy of malignant melanoma Cancer 49:1387 (1982). Hollinshead A, Miller H, Tanner K, Lee O, and Klausia J. Soluble cell membrane antigens associated with bladder cancer. Cancer Immunol. Immunother. 5:93-103, (1978). Hollinshead A, Herberman R, Jaffurs W, et al. Soluble membrane antigens of human malignant melanoma cells. Cancer 34:1235-1243, (1974). Hollinshead A, Jaffurs W, Alpert L, et al. Isolation and identification of soluble skin-reactive membrane antigens of malignant and normal human breast cells. Cancer Res. 34:2961-2968, (1974). Köhler G. and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497 (1975). Kulasingam SL, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities. JAMA 288:1749-1757 (2002). Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Annals of Internal Medicine 132:810-819 (2000). Takita H, Hollinshead AC, Adler RH, et al. Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: a 5 year survival analysis. J Surg Oncol. 46(1):9-14, (1991). |